A bill to amend title 35 of the United States Code to provide a patent extension for certain drug products.
Amends the patent laws to extend the term of any patent encompassing a new drug product subject to the labeling requirements for oral hypoglycemic drugs of the sulfonylurea class as promulgated by the Food and Drug Administration on a specified date.
Forwarded by Subcommittee to Full Committee (Amended).
Committee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended).
Reported to House (Amended) by House Committee on The Judiciary. Report No: 98-1060.
Reported to House (Amended) by House Committee on The Judiciary. Report No: 98-1060.
Placed on Private Calendar No: 71.
Called up by House as Privileged Matter.
Passed/agreed to in House: Passed House (Amended) by Voice Vote.
Passed House (Amended) by Voice Vote.
Received in the Senate.
Held at the desk by unanimous consent.
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
Passed Senate without amendment by Voice Vote.
Measure Signed in Senate.
Presented to President.
Presented to President.
Signed by President.
Signed by President.
Became Private Law No: 98-46.
Became Private Law No: 98-46.
Enacted as Private Law 98-46
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line